CoChat

Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma

Open access
Algazi, Alain P., Twitty, Christopher G., Tsai, Katy K., Le, Mai, Pierce, Robert, Browning, Erica, Hermiz, Reneta, Canton, David A., Bannavong, Donna, Oglesby, Arielle, Francisco, Murray, Fong, Lawrence, Pittet, Mikael J., Arlauckas, Sean P., Garris, Christopher, Levine, Lauren P., Bifulco, Carlos, Ballesteros-Merino, Carmen, Bhatia, Shailender, Gargosky, Sharron, Andtbacka, Robert H.I., Fox, Bernard A., Rosenblum, Michael D., Daud, Adil I. · 2020 · Clinical Cancer Research
Cited by 147

The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.

Abstract

Purpose: Tumors with low frequencies of checkpoint positive tumor-infiltrating lymphocytes (cpTIL) have a low likelihood of response to PD-1 blockade. We conducted a prospective multicenter phase II trial of intratumoral plasmid IL-12 (tavokinogene telseplasmid; “tavo”) electroporation combined with pembrolizumab in patients with advanced melanoma with low frequencies of checkpoint positive cytotoxic lymphocytes (cpCTL). Patients and Methods: Tavo was administered intratumorally days 1, 5, and 8 every 6 weeks while pembrolizumab (200 mg, i.v.) was administered every 3 weeks. The primary endpoint was objective response rate (ORR) by RECIST, secondary endpoints included duration of response, overall survival and progression-free survival. Toxicity was evaluated by the CTCAE v4. Extensive correlative analysis was done. Results: The combination of tavo and pembrolizumab was well tolerated with adverse events similar to those previously reported with pembrolizumab alone. Patients had a 41% ORR (n = 22, RECIST 1.1) with 36% complete responses. Correlative analysis showed that the combination enhanced immune infiltration and sustained the IL-12/IFNγ feed-forward cycle, driving intratumoral cross-presenting dendritic cell subsets with increased TILs, emerging T cell receptor clones and, ultimately, systemic cellular immune responses. Conclusions: The combination of tavo and pembrolizumab was associated with a higher than expected response rate in this poorly immunogenic population. No new or unexpected toxicities were observed. Correlative analysis showed T cell infiltration with enhanced immunity paralleling the clinical activity in low cpCTL tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-19-2217

Cites

16 of 16 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 16 references

Cited by

See all 147

Metadata

Authors
Algazi, A. P., Twitty, C. G., Tsai, K. K., Le, M., Pierce, R., Browning, E., Hermiz, R., Canton, D. A., Bannavong, D., Oglesby, A., Francisco, M., Fong, L., Pittet, M. J., Arlauckas, S. P., Garris, C., Levine, L. P., Bifulco, C., Ballesteros-Merino, C., Bhatia, S., Gargosky, S., Andtbacka, R. H. I., Fox, B. A., Rosenblum, M. D., & Daud, A. I.
Venue
Clinical Cancer Research
Published
2020-06-15
Volume
26
Issue
12
Pages
2827-2837
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W3023565412
Cited by
147
References
16
FWCI
6.98
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-19-2217
The paper
Algazi, A. P., Twitty, C. G., Tsai, K. K., Le, M., Pierce, R., Browning, E., Hermiz, R., Canton, D. A., Bannavong, D., Oglesby, A., Francisco, M., Fong, L., Pittet, M. J., Arlauckas, S. P., Garris, C., Levine, L. P., Bifulco, C., Ballesteros-Merino, C., Bhatia, S., . . . Daud, A. I. (2020). Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-19-2217

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.